Type 1 diabetes development in the NOD mouse model is widely reported to be dependent on high-level production by autoreactive CD4 + and CD8 + T cells of interferon-g (IFN-g), generally considered a proinflammatory cytokine. However, IFN-g can also participate in tolerance-induction pathways, indicating it is not solely proinflammatory. This study addresses how IFN-g can suppress activation of diabetogenic CD8 + T cells. CD8 + T cells transgenically expressing the diabetogenic AI4 T-cell receptor adoptively transferred disease to otherwise unmanipulated NOD.IFN-g null , but not standard NOD, mice. AI4 T cells only underwent vigorous intrasplenic proliferation in NOD.IFN-g null recipients. Disease-protective IFN-g could be derived from any lymphocyte source and suppressed diabetogenic CD8 + T-cell responses both directly and through an intermediary nonlymphoid cell population. Suppression was not dependent on regulatory T cells, but was associated with increased inhibitory STAT1 to STAT4 expression levels in pathogenic AI4 T cells. Importantly, IFN-g exposure during activation reduced the cytotoxicity of human-origin type 1 diabetes-relevant autoreactive CD8 + T cells. Collectively, these results indicate that rather than marking the most proinflammatory lymphocytes in diabetes development, IFN-g production could represent an attempted limitation of pathogenic CD8 + T-cell activation. Thus, great care should be taken when designing possible diabetic intervention approaches modulating IFN-g production.
Interferon-g (IFN-g) is a crucial cytokine in various immune responses produced by multiple cell types (1, 2) and has long been considered a contributor to autoimmune type 1 diabetes (T1D). This paradigm is partly based on reports IFN-g expression correlates with disease progression in BB rats (3), NOD mice (4), and humans (5) , and pharmacologically blocking this cytokine can inhibit diabetes (6, 7) . Numerous immunomodulatory protocols also reportedly inhibit diabetes development in NOD mice by skewing cytokine production by pathogenic T cells from a Th1 (including IFN-g) to Th2 profile (reviewed in Ref. 8 ). However, other evidence indicates IFN-g can exert nonredundant immunoregulatory roles suppressing at least some components of diabetes development. This includes a report diabetes is inhibited in IFN-g-treated NOD mice (9) . Treatment of NOD mice with syngeneic antigen-presenting dendritic cells (DCs) matured ex vivo with IFN-g also reportedly inhibits diabetes development (10) . Furthermore, the ability of some nonspecific immunostimulatory agents, including complete Freund's adjuvant and Bacillus Calmette-Guérin vaccine, to inhibit diabetes onset in NOD mice requires IFN-g production (11) (12) (13) . Immunological tolerance-induction mechanisms, such as indoleamine 2,3-dioxygenase (IDO) production by DCs as well as eliciting activation-induced cell death (AICD) responses by autoreactive T cells, also require IFN-g (14) (15) (16) . Genetic ablation of IFN-g or its receptor also has little effect on diabetes development in NOD mice (11, (17) (18) (19) . Such contradictory effects complicate determination of the overall contribution of IFN-g to diabetes development.
One potential explanation for the above collective findings might be that IFN-g exerts supportive, suppressive, or neutral effects on diabetes development in a manner both under temporal control and influenced by tissue microenvironment differences. If this theory is correct, then measuring IFN-g expression by T cells as a surrogate for their diabetogenic activity is an oversimplification not accounting for the diverse, possibly including diseaseprotective, effects of this cytokine. Indeed, our current work indicates diabetic interventions focused on suppressing IFN-g production could, in some circumstances, actually promote pathogenic CD8 + T-cell responses.
RESEARCH DESIGN AND METHODS

Mice
NOD/ShiLtDvs mice were maintained in a specific pathogen-free research colony. .AI4), have been described (11, 18, (20) (21) (22) (23) (24) (25) .
AI4 T-Cell Transfer of Diabetes
Recipient mice that did or did not receive a preconditioning 600-cGy irradiation dose were injected i. .AI4 splenocytes were prelabeled with 2.5 mmol carboxyfluorescein succinimidyl ester (CFSE). After 4 or 8 days, viable AI4 T cells from spleens and pancreatic lymph nodes (PLNs) were identified by flow cytometry using a combination of CFSE, antibodies against CD8 (53-6.7) and CD3 (145-2C11), and a previously described clonotypic tetramer (26) (Supplementary Fig. 1 ). Expression of T-cell surface markers was assessed using CD44-(IM7.8.1) and CD62L-specific (MEL-14) antibodies.
PCR Analysis of IFN-g mRNA Expression
Splenocytes from unmanipulated NOD mice or those injected i. 
TCRVa8
2 ). cDNA was generated using an RNeasy kit (74004; Qiagen). Primer sequences are as follows: IFN-g forward (59-ACTGGCAAAAG GATGGTGAC-39) and reverse (59-TGAGCTCATTGAATG CTT-39); and 18sRNA forward (59-CCGCAGCTAGGAA-39) and reverse (59-CGAACCTCCGACT-39). Samples and primers were combined with Power SYBR Green PCRMaster Mix (4367659; Applied Biosystems) and acquired on an Applied Biosystems ViiA7 Real Time PCR System (Life Technologies).
Treg Activity and STAT Expression Analyses
Viable stained cells were detected using LSR II or FACSCalibur flow cytometers (BD Biosciences). Data were analyzed using FlowJo software (Tree Star, Palo Alto, CA). A previously described flow cytometry assay (27) assessed the ability of NOD and NOD.IFN-g null Tregs to inhibit CD4 + CD25 2 T-cell proliferation in vitro. To assess intracellular STAT expression, extracellular antigens were stained prior to fixation with BD Cytofix/Cytoperm (BD Biosciences) for 10 min at 37°C and then incubated for 30 min at 4°C with BD Perm Buffer III (BD Biosciences). Previously validated STAT antibodies (28) were purchased from BD Biosciences: STAT1 (AF647-conjugated 1/STAT1) and STAT4 (unconjugated 8/STAT4 followed by allophycocyanin-conjugated Anti-Mouse A85-1). Transferred AI4 T cells were identified using FITC-CD8a (53-6.72) antibody and phycoerythrin-labeled YAIENYLEL/H-2D b tetramer (NIH Tetramer Core Facility, Atlanta, GA).
Human CD8
+ T-Cell Transduction and Cell-Mediated Lysis Assays
CD8
+ T cells were enriched from whole blood of five healthy human subjects using the RosetteSep Enrichment kit (STEMCELL Technologies, Vancouver, British Columbia, Canada). Cells were stained with CD8 (clone SK1; BioLegend), CD45RA (clone HI100; BioLegend), and CD45RO (clone UCHL1; BioLegend) and sorted for naive CD8 + T cells (CD8
2 ) using an FACSAria III (BD Biosciences). CD8 + T cells were plated at 2.5 3 10 5 /well in 1 mL complete RPMI 1640 (10% heat-inactivated FCS, GE Healthcare; 2 mmol L-glutamine, Thermo Fisher Scientific; 5 mmol sodium pyruvate, Cellgro; 5 mmol nonessential amino acids, Life Technologies; 5 mmol HEPES, Cellgro; 50 mg/mL penicillin/streptomycin, Gemini Bio Products; and 50 mmol 2-mercaptoethanol, Sigma-Aldrich), activated with Human T-Activator CD3/CD28 Dynabeads (Thermo Fisher Scientific), and cultured with or without human recombinant IFN-g (1,000 U/mL; R&D Systems). At 48 h, cells were transduced with lentivirus produced as previously described (29) encoding either HLA-A*02-01-restricted islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-autoreactive or irrelevant MART-1-specific TCRs (pCCL.IGRPopt.eGFP or LV.Mart1.TCR.RK, respectively) (30) (31) (32) . Transductions were conducted in the presence of protamine sulfate (8 mg/mL; Sigma-Aldrich) and spinnoculated for 30 min at 32°C and 1,000 3 g. Complete media and interleukin (IL)-2 (PeproTech) were added and cells incubated at 37°C in 5% CO 2 6 IFN-g and IL-2 (100 U/mL) every other day until day 9. Cells were then washed and cryopreserved in 90% FCS/10% DMSO prior to use.
IGRP-or MART-1-specific CD8 + T cells were added, in triplicate, at a series of effector-to-target (E:T) ratios to wells containing 10,000 HLA-A*0201 + class I-positive human BetaLox5 (BL5) target cells. To enhance their sensitivity to CD8 + T cell-mediated lysis, BL5 target cells were pre-exposed to 1,000 U/mL IFN-g for 24 h and washed before use in the cytotoxicity assay. Target cells were preloaded with 51 Cr as previously described (33) . Target cell lysis was assessed after overnight incubation by measuring 51 Cr release using a Wallac Wizard g counter (PerkinElmer). Percentage specific lysis was calculated as follows: Fig. 1B and C) . Activated AI4 T cells also accumulated in the spleens of mutant, but not wild-type, recipients by 8 days posttransfer (Fig. 1D) . Thus, IFN-g reduces the frequency of activated AI4 T cells in vivo.
IFN-g Production by Any Lymphocytes Inhibits AI4 T-Cell Activation
We tested what host cell types produce IFN-g-suppressing activity of diabetogenic AI4 T cells transferred into otherwise unmanipulated standard NOD recipients. Initially, we compared IFN-g mRNA transcript levels in different splenocyte populations in standard NOD mice injected or not 3 days previously with AI4 T cells. Transferred AI4 T cells increased IFN-g mRNA expression in host-type CD4 + T cells ( Fig. 2A ). Host-type B cells and CD8 + T cells in unmanipulated NOD mice expressed baseline levels of IFN-g mRNA transcripts remaining unchanged following AI4 T-cell infusion ( Fig. 2A) .
We next tested whether IFN-g-intact or -deficient CD4 + T cells differentially affected the ability of cotransferred AI4 T cells to induce diabetes in lymphopenic NOD.scid recipients. Compared with those infused with AI4 T cells alone, diabetes development was, respectively, accelerated and suppressed in NOD.scid recipients also receiving IFN-gdeficient or -intact CD4 + T cells (Fig. 2B ). AI4 T cell-induced diabetes was slower in NOD.scid recipients coengrafted with IFN-g-deficient CD4
+ T cells than NOD.IFN-g null hosts receiving these pathogenic effectors (Fig. 1A) . This is likely because of comparatively smaller numbers of IFN-g-deficient CD4
+ T cells in NOD.scid recipients. IFN-g converts CD4 + CD25 2 effector T cells to immunosuppressive FoxP3 + Tregs in several settings (35, 36) . Thus, we hypothesized Tregs may suppress the activity of AI4 T cells infused into standard, but not IFN-gdeficient, NOD mice. Both the frequency and total numbers of CD4 + CD25 + FoxP3 + Tregs were unexpectedly greater in IFN-g-deficient than standard NOD mice, although with no differences in FoxP3 expression levels ( + T cells, anti-CD25 treatment failed to break the resistance of nonirradiated NOD mice to AI4 T-cell transfer (Fig. 2E) . These collective results indicated Tregs are not the CD4 + T-cell population mediating IFN-g-dependent inhibition of diabetogenic AI4 T cells.
Subsequent studies assessed what immunological cell populations other than Tregs mediate IFN-g-dependent suppression of diabetogenic CD8 + T cells. AI4 T cells were infused into NOD.IFN-g null recipients along with NOD splenocytes lacking various lymphocyte populations (Supplementary Fig.  2 and Table 1 ). As controls, NOD.IFN-g null recipients injected with AI4 T cells and either total NOD.IFN-g null or standard NOD splenocytes were, respectively, entirely susceptible and resistant to diabetes development (Table 1) . AI4 recipients coinfused with NOD splenocytes lacking either CD4 + or CD8 + T cells or B cells were diabetes resistant. However, NOD splenocytes lacking all three lymphocyte subsets failed to inhibit AI4 T cell-induced diabetes. These results indicated IFN-g produced by any lymphocyte population blocks diabetogenic AI4 T-cell activity. Subsequent experiments supporting this conclusion found AI4 T cells induce diabetes when infused into B and T cell-deficient NOD.Rag1 null mice, but not NOD stocks capable of producing at least one lymphocyte population ( Table 2) Fig. 3 ).
IFN-g Directly and Indirectly Inhibits Diabetogenic AI4 T Cells
We tested whether IFN-g directly suppresses AI4 T-cell activity. NOD.Rag1 null .AI4 splenocytes, containing both AI4 T cells and myeloid lineage-derived cells, were transferred into either nonirradiated standard NOD mice or a stock lacking the IFN-g receptor (NOD.IFN-gR null ).
Although NOD.IFN-gR null recipients produce IFN-g, only donor splenocytes can respond to this cytokine. Like standard NOD mice, the NOD.IFN-gR null stock was resistant 2 effectors from both strains (assessed by flow cytometic detection of CFSE dilution). E: Beginning at 6 weeks of age, NOD female mice received three biweekly i.p. injections with the Treg-depleting CD25-specific PC61 antibody or a rat IgG1 isotype control. One week after the first treatment, mice in both groups were injected i.v. with 1 3 10 7 NOD.Rag1 null .AI4 splenocytes and subsequently monitored for diabetes. Survival curves compared by log-rank test. *P < 0.05 determined by one-way ANOVA, **P < 0.01 determined by unpaired t test. Teff, effector T cell; WT, wild type.
to AI4 splenocyte-induced diabetes (Fig. 3A) . These results indicated IFN-g production by host or donor lymphocytes might either directly suppress diabetogenic AI4 T cells or may do so in a nonmutually exclusive indirect fashion by altering activities of a cotransferred myeloid population(s). To distinguish between these possibilities, 1 3 10 6 purified (.90%) AI4 T cells were injected into NOD, NOD.IFN-g null , and NOD.IFN-gR null recipients subsequently monitored for diabetes. Purified AI4 T cells only induced diabetes in NOD.IFN-g null recipients (Fig. 3B) . These results indicated IFN-g could directly suppress AI4 T-cell diabetogenic activity.
The above results did not preclude the possibility IFN-g also partially suppresses AI4 T cells by functionally altering a host-type intermediary cell population. To test this possibility, purified AI4 T cells were cotransferred with purified NOD CD4 + T cells as a source of IFN-g into NOD.Rag1 . Recipients were monitored for diabetes development over 70 days instead of 2 to 3 weeks because adoptive transfer of disease takes longer into lymphopenic NOD.Rag1 null mice than lymphocytesufficient hosts. Diabetes developed at a significantly lower level in IFN-gR intact than deficient NOD.Rag1 null recipients (Fig. 3C) . These results demonstrated IFN-g also effects a host-origin nonlymphocyte population that indirectly suppresses diabetogenic CD8 + T cells. Finally, we tested whether IFN-g suppresses AI4 T cells through effects on CD4 + T cells. AI4 T cells were injected into NOD. Rag1 null recipients with purified splenic CD4 + T cells from NOD or NOD.IFN-gR null donors. Diabetes developed at the same low rate in both groups of recipients (Fig. 3D) , indicating that although they can produce AI4 T cell-inhibiting IFN-g, CD4 + T cells do not respond to this cytokine in ways allowing them to suppress such pathogenic effectors. These collective results indicate IFN-g suppresses diabetogenic CD8
+ T cells both directly and through effects on nonlymphoid cells.
AI4 T Cells in Diabetes-Resistant Hosts Upregulate STAT1
After eliminating possible contributions from multiple components of IFN-g-triggered signaling pathways (complete list noted in the DISCUSSION), we tested if inducing differing STAT1 and STAT4 expression levels in transferred AI4 T cells could contribute to their variable diabetogenic activity in the analyzed host types. This was done based on reports that elevated STAT1 to STAT4 expression levels suppresses T cell-proliferative capacity (28,37). AI4 T cells taken directly from the different recipients had no (Fig. 4A  and B) . STAT4 levels were similar in AI4 T cells posttransfer into both NOD than NOD.IFN-g null recipients (Fig. 4A and  B) . In addition to the transferred AI4 T cells, STAT1, but not STAT4, expression was also higher in host-type NOD than NOD.IFN-g null CD8 + T cells (Fig. 4C) . STAT1 levels remained similar in AI4 T cells prior to and after transfer into NOD.IFN-g null recipients (Fig. 4D) . Although not inducing diabetes in either otherwise unmanipulated NOD or NOD.IFN-gR null recipients, infused AI4 T cells acquired even higher levels of STAT1, but not STAT4, expression in the latter environment (Fig. 4E) . Such increased STAT1 expression by donor AI4 T cells was specifically induced by IFN-g signaling, as this did not occur among host-type NOD.IFN-gR null
CD8
+ T cells (Fig. 4F) . Thus, an IFN-g-dependent increase in STAT1 but not STAT4 expression by AI4 T cells transferred into nonirradiated NOD and NOD.IFN-gR null , but not NOD.IFN-g null , recipients could explain why such effectors only elicit diabetes in the latter host type. AI4 T cells transfer diabetes to preirradiated NOD mice (34) . Thus, we hypothesized if a posttransfer elevation in STAT1 expression by AI4 T cells explains why these effectors fail to elicit diabetes development in otherwise unmanipulated NOD recipients, this should not occur in preirradiated hosts. Two days after transfer into 600-cGy-irradiated recipients, AI4 T cells expressed STAT1 at similar levels in NOD and NOD.IFN-g null hosts (Fig. 4G) . In contrast, AI4 T cells transferred into irradiated NOD.IFN-gR null mice expressed higher total STAT1 levels than in NOD or NOD.IFN-g null recipients (Fig. 4G) , with no differences observed among the three groups for STAT4 (Fig. 4H ). Hence, we tested whether NOD.IFN-gR null recipients, after irradiation preconditioning, were also more resistant to AI4 T cell-mediated diabetes. AI4 T cells transferred diabetes to preirradiated NOD and NOD.IFN-g null but not NOD.IFN-gR null mice (Table 3) . Collectively, these data indicate, at least under some adoptive transfer conditions, diabetogenic CD8 + T cells can be functionally suppressed in an IFN-gdependent fashion through induction of elevated STAT1 expression. 
IFN-g Directly Inhibits Human Diabetogenic CD8 + T Cells
We also determined whether IFN-g could directly suppress human diabetogenic CD8 + T cells in vitro. Purified CD8 + T cells from five healthy individuals were transduced with lentiviral vectors encoding a TCR recognizing an HLA-A*02-01-restricted epitope derived from the b-cell autoantigen IGRP (30) . The transduction process requires activation of CD8 + T cells using anti-CD3/CD28-coated Dynabeads (33) and was performed in both the presence and absence of IFN-g. CD8 + T cells were thoroughly washed posttransduction to ensure all excess cytokine was removed. Flow cytometric analyses of EGFP expression confirmed equivalent efficiency of TCR transduction between IFN-g-treated and -untreated groups. CD8 + T cells were added at a series of E:T ratios to 51 Cr-labeled HLA-A*0201 class I-positive BL5 human b-cells used as targets (38, 39) . Control effectors were CD8 + T cells transduced to express a MART-1-specific TCR recognizing an HLA-A*02-01-restricted melanoma antigen not present in BL5 cells. Pre-exposure of the IGRP-specific CD8 + T cells to IFN-g reduced their cytotoxic capacity especially at high E:T ratios (Fig. 5A) . Lysis of b-cells by IGRP-specific CD8 + T cells was antigen driven because MART-1-specific CD8 + T cells had little effect on such targets (Fig. 5B) . Hence, IFN-g can also directly suppress the activity of human IGRP-autoreactive CD8 + T cells.
DISCUSSION
Reducing circulating IFN-g has been suggested as a means to suppress diabetogenic CD8 + T cells, ultimately mediating pancreatic b-cell destruction (8) . However, IFN-g also has effects inhibiting autoimmunity, including inducing IDO expression by tolerogenic DCs (14, 15) . IFN-g is also required for eliciting AICD controlling the expansion and persistence of T cells (16) . These mechanisms may explain why recombinant IFN-g (9) or DCs conditioned by this cytokine (10) can inhibit diabetes development in NOD mice. The present work demonstrates, at least under some conditions, that pathogenic CD8 + T-cell activation is one component of diabetes development directly sensitive to IFN-g inhibition in both mice and humans. IFN-g from any lymphocyte source blocks diabetes induced by adoptively transferred AI4 T cells through a Treg-independent process. Surprisingly, B cells, not normally associated with IFN-g expression, were equally effective as CD8 + or CD4 + T cells at suppressing diabetes induced by adoptively transferred AI4 T cells. The subset of B cells suppressing diabetogenic CD8 + T-cell responses may resemble the previously described B effector 1 population known to express significant levels of IFN-g (2) . Although it would require multiple generations of further breeding, it would ultimately be of value to assess whether IFN-g produced by transferred AI4 T cells themselves influences their differential ability to induce diabetes in unirradiated NOD and NOD.IFN-g null recipients. Lymphocyte-derived IFN-g at least in part directly suppresses diabetogenic CD8 + T-cell activation. IFN-g also acted on one or more intermediary nonlymphoid cell types that in turn suppress diabetogenic CD8 + T-cell responses. Although these intermediary cell types still await definitive identification, one good candidate is DCs, because when conditioned with IFN-g ex vivo they can, after adoptive transfer, suppress spontaneous diabetes in NOD mice (10) . It should be noted we tested whether IFN-g-induced IDO production by DCs suppressed diabetogenic CD8 + T cells in our model system. AI4 splenocytes were injected into standard NOD mice treated with or without the IDO inhibitor 1-methyl tryptophan. Inhibiting IDO did not alter the resistance of otherwise unmanipulated NOD mice to AI4 T cell-induced diabetes development, indicating IFN-g does not control the activation of such pathogenic effectors through this enzyme.
AI4 T cells transferred into nonirradiated NOD or NOD.IFN-g null recipients also did not differ in expression of IL-7Ra, TIM-3, programmed cell death-1, GITR, CD25, or IFN-aR molecules associated with immunological activation or inhibition. Hence, pathways in which these molecules participate are unlikely to contribute to variable diabetes induction by AI4 T cells in these two host types. Fas and KLRG1 involved in apoptosis induction are also unlikely to reduce AI4 T cell-induced diabetes in NOD mice, as both molecules were upregulated equally on such effectors transferred into disease-susceptible NOD.IFN-g The ability of AI4 T cells to induce diabetes in NOD.IFNg null , but not standard NOD mice, was associated with greater proliferation of such effectors in the former recipients. In early antiviral responses, the interplay between type I IFNs and STATs is an important checkpoint determining whether T-cell responses are stimulated or inhibited (28, 37) . IFN-a can elicit STAT1-dependent antiproliferative effects on T cells (37) . However, a lymphocytic choriomeningitis infection model demonstrated STAT1 levels decrease in antigen-specific CD8 + T cells that concordantly increase STAT4 expression. This allows virus-specific T cells to overcome the initial antiproliferative effects of IFN-a (28, 37) . Serum IFN-a was not detected in NOD or NOD.IFN-g null recipients either before or after AI4 transfer. However, in the nonproliferative AI4 cells transferred into IFN-g intact NOD mice ( Fig.  4A and B) , we observed elevated total STAT1 expression levels by these effectors, a phenotype previously observed with Hep3B cells (40) . We found no differences in p-STAT1 or p-STAT4 with or without stimulation in vitro with IFN-b. AI4 T cells exhibited an IFN-g-dependent elevation in total STAT1 expression, but with unchanged STAT4 levels only when transferred into otherwise unmanipulated recipients in which such effectors failed to elicit diabetes development (NOD and NOD.IFN-gR null ). Interestingly, STAT1 but not STAT4 expression was increased to a greater extent in AI4 T cells transferred into otherwise unmanipulated NOD.IFN-gR null than NOD recipients. Furthermore, unlike the case for NOD recipients, transferred AI4 T cells also failed to induce diabetes in irradiation-conditioned NOD.IFN-gR null mice. The resistance of NOD.IFN-gR null mice under both transfer conditions to AI4 T cell-induced diabetes is likely because of higher IFN-g levels in this strain after immune stimulation compared with standard NOD mice (18) , probably owing to lessened IFN-gR-mediated sequestration of this cytokine. Collectively, these results implicate an IFN-gregulated increase in STAT1 but not STAT4 expression levels as mechanistically contributing to inhibition.
Antibody blockade or IFN-g administration studies would affect both transferred AI4 and host-type cells. Thus, we posit the future creation of NOD.Rag1 + T cells transduced in the presence or absence of IFN-g. BL5 cells were pre-exposed to 1,000 U/mL IFN-g and washed before they were used in the cell-mediated lympholysis assays. P values calculated using a paired t test.
T cells, and deviations from this range, both positively and negatively, might alter expansion of such effectors. Cells that are either STAT1 deficient, have inactive mutant forms of STAT1a, or only express the STAT1b isoform are resistant to the antiproliferative effects of IFN-g (42) . Therefore, although difficult to create, generating NOD.Rag1 null .AI4 mice expressing only a full-length a or COOH-terminaltruncated b isoform of STAT1 could further help to unravel the seemingly contradictory roles of IFN-g and STATs in diabetogenic CD8 + T-cell responses. Our current results might appear to contradict a previous report showing the insulin-specific CD8 + T-cell clone TGNFC8 transfers diabetes less efficiently to NOD.IFN-g null than standard NOD mice (43) . It is important to note the TGNFC8 clone is poorly suited to studying events controlling the initial in vivo activation of diabetogenic CD8 + T cells. This is because the TGNFC8 clone must be preactivated in culture to adoptively transfer disease (44, 45) . Because activated virus-specific T cells were resistant to IFN-a-mediated tolerance [via prior TCR stimuli-mediated upregulation of STAT4 and downregulation of STAT1 (28)], the preactivation of TGNFC8 cells likely alters their ability to respond to the in vivo IFN-g-mediated protection we currently describe. In contrast, the current study used freshly isolated and initially naive AI4 T cells capable of activation and disease induction after adoptive transfer. Thus, they are subject to all effects controlling this process, including modulation by IFN-g.
Our collective findings indicate that the temporal timing of IFN-g signaling in relation to antigen-mediated activation of diabetogenic CD8 + T cells may be key to whether they are pathogenically activated or suppressed. This raises a possible cautionary note that treating humans at risk for T1D with agents limiting or skewing IFN-g production may accelerate disease if significant numbers of autoreactive CD8 + T cells are already present. 
